RxDoctor Payments DataLook up a doctor →

Rebecca Pace, MD

Internal Medicine · Jackson, MSNPI 1003103516

Payments from drug & device makers

$8,440in general payments, 2019–2025

Across 471 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Amgen$1K
  • Novo Nordisk$922
  • AstraZeneca$759
  • Boehringer Ingelheim$552
  • Corcept Therapeutics$350
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,418100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,440 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$116,940
Medicare patients
451
Services billed
3,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$366,013
MounjaroTirzepatide190$236,800
TrulicityDulaglutide162$186,267
JardianceEmpagliflozin122$149,546
Tresiba Flextouch U-200Insulin Degludec105$110,207
FarxigaDapagliflozin Propanediol85$86,419
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog62$50,434
Tresiba Flextouch U-100Insulin Degludec79$42,809
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$40,126
Xultophy 100-3.6Insulin Degludec/Liraglutide31$33,517
Novolog FlexpenInsulin Aspart108$30,853
RybelsusSemaglutide29$29,740
Humulin R U-500 KwikpenInsulin Regular, Human17$25,330
Synjardy XrEmpagliflozin/Metformin Hcl15$21,555
Gvoke Hypopen 2-PackGlucagon24$16,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog$922$432,120310 claims
Lilly USA, LLCMounjaro, Trulicity$1,476$423,066352 claims
Boehringer IngelheimJardiance, Synjardy Xr$552$171,101137 claims
AstraZenecaFarxiga$759$86,41985 claims
MerckJanuvia$25$7,35012 claims
AbbVieSynthroid$282$5,16683 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →